Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

CeriBell, Inc. (CBLL) Financial Statements

CeriBell, Inc. (CBLL) reported trailing twelve-month revenue of $102.0M (up 31.7% year on year) and net income of -$66.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$54.7M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CBLLCeriBell, Inc.Follow CBLL — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.0B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
3 Nov, in 10 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue65.489.1102.0
Gross profit56.878.390.6
Research & development13.619.123.0
Operating income-39.7-58.4-70.0
Pre-tax income-40.5-53.4-66.0
Income tax0.00.00.0
Net income-40.5-53.4-66.0
Diluted EPS ($)-3.39-1.46-1.76
Diluted shares (mn)11.936.5—

USD millions · SEC XBRL

CeriBell, Inc. — questions

What is CeriBell, Inc.'s revenue?
$102.0M over the twelve months to 2026-06-30, up 31.7% year on year, from its 10-Q and 10-K filings.
What is CeriBell, Inc.'s net income?
-$66.0M over the twelve months to 2026-06-30.
What is CeriBell, Inc.'s free cash flow?
-$54.7M over the twelve months to 2026-06-30.
What are CeriBell, Inc.'s diluted earnings per share?
$-1.76 over the twelve months to 2026-06-30.

Every figure on this page comes from CeriBell, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.